Addex to Present at the Swiss Equities Baader Virtual Conference
January 11, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 06, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Raises $10.0 Million in Equity Financing
December 17, 2021 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Provides Year End Pipeline Development Update
December 15, 2021 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex to Present at the Virtual German Equity Forum
November 18, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
November 15, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
November 15, 2021 01:00 ET
|
Addex Therapeutics
Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and...
Addex Reports Q3 2021 Financial Results and Provides Corporate Update
November 04, 2021 02:00 ET
|
Addex Therapeutics
CHF15.5M ($16.6M) of cash and cash equivalents at September 30, 2021Cash used in Q3 2021 of CHF2.6MDipraglurant Phase 2 blepharospasm clinical trial InitiatedPhase 2b/3 dipraglurant study in...
Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021
November 01, 2021 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 1, 2021 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex to Present at the Investors’ Day hosted by Voxia Communication
October 06, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...